### Special Features

**CCR Translations**
- **BAP1tism of a Tumor Suppressor**
  - Scott E. Woodman
  - See article p. 408

**Molecular Pathways**
- **Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis**
  - William C. Dougall

**Perspective**
- **New Challenges in Endpoints for Drug Development in Advanced Melanoma**
  - Antoni Ribas, Peter Hersey, Mark R. Middleton, Helen Gogas, Keith T. Flaherty, Vernon K. Sondak, and John M. Kirkwood

**Review**
- **Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects**
  - Michaela R. Reagan and Irene M. Ghobrial

### Human Cancer Biology

**Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution**
- Brooke E. Sylvester, Dezheng Huo, Andrey Khramtsov, Jing Zhang, Rana V. Smalling, Sope Olugbile, Blase N. Polite, and Olufunmilayo I. Olopade

**A Noncanonical Fli3ITD/NF-xB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia**
- Raja Subramaniam Shanmugam, Padmaja Gade, Annique Wilson-Weekes, Hamid Sayar, Attaya Suvannasankha, Chirayu Goswami, Lang Li, Sushil Gupta, Angelo A. Cardoso, Tareq Al Baghdadi, Katie J. Sargent, Larry D. Cripe, Dhananjaya V. Kalvakolanu, and H. Scott Boswell

### Cancer Therapy: Preclinical

**Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma**
- Solange Landreville, Olga A. Agapova, Katie A. Matatall, Zachary T. Kneass, Michael D. Onken, Ryan S. Lee, Anne M. Bowcock, and J. William Harbour
  - See commentary p. 233

**Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells**
- Sascha Dietrich, Oliver H. Krammer, Esther Hahn, Claudia Schäfer, Thomas Giese, Michael Hess, Theresa Trettin, Michæl Rieger, Jennifer Hülle, Thorsten Zenz, Anthony D. Ho, Peter Dreger, and Thomas Luft

---

**Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome**
- Rossitza Lazoza, Robert L. Camp, Vincent Klump, Summar F. Siddiqui, Ravi K. Amaravadi, and John M. Pawelek

**Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways**
- Hiu-Fung Yuen, Ka-Kui Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osamu Sharaf Eldin, Ken O’Byrne, Pasi Janne, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, and Mohamed El-Tanani

**Serum Interleukin-6, Insulin, and HOMA-IR in Male Individuals with Colorectal Adenoma**
- Yu Sasaki, Hiroaki Takeda, Takeshi Sato, Tomohiko Oriti, Shoichi Nishiie, Ko Naqino, Daisuke Iwano, Takao Yaoto, Kazuya Yoshizawa, Hideki Saito, Yasuhisa Tanaka, and Sumio Kawata

**Lifetime Cancer Risks in Individuals with Germline PTEN Mutations**
- Min-Han Tan, Jessica L. Mester, Joanne Ngeow, Lisa A. Rybicki, Mohammed S. Olof, and Charis Eng
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>442</td>
<td>Bexarotene via CBP/p300 Induces Suppression of NF-κB-Dependent Cell Growth and Invasion in Thyroid Cancer</td>
<td>Audrey Cras, Béatrice Politis, Nicole Balitrand, Diane Darsin-Bettinger, Pierre Yves Boelle, Bruno Cassinat, Marie-Elisabeth Toubert, and Christine Chomienne</td>
</tr>
<tr>
<td>454</td>
<td>Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth</td>
<td>Andreas Wicki, Christoph Bachlitz, Annette Orleth, Reto Ritschard, Emke Albrecht, Richard Herrmann, Gerhard Christofori, and Christoph Mamot</td>
</tr>
<tr>
<td>465</td>
<td>EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells</td>
<td>Michele Cioffi, Jorge Dorado, Patrick A. Haeuerle, and Christopher Heeschen</td>
</tr>
<tr>
<td>475</td>
<td>CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells</td>
<td>Daniela Trisciuoglio, Vlenna Ragazzoni, Andrea Pelosi, Mariana Desideri, Simone Carradori, Chiara Gabellini, Giovanna Maresca, Riccardo Nescaletti, Daniela Secchi, Adriana Bolasco, Bruna Bizzarri, Chiara Cavaliere, Igea D’Agnano, Patrizia Filetici, Lucia Ricci-Vitiani, Maria Giulia Rizzo, and Donatella Del Bufalo</td>
</tr>
<tr>
<td>499</td>
<td>VTX-2337 Is a Novel TL8 Agonist That Activates NK Cells and Augments ADCC</td>
<td>Hailing Lu, Gregory N. Dietsch, Maura-Ann H. Matthews, Yi Yang, Smita Ghanekar, Margaret Inokuma, Maria Suni, Vernon C. Maino, Katherine E. Henderson, James Jeffry Howbert, Mary L. Disis, and Robert M. Hershberg</td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

**CANCER THERAPY: CLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>510</td>
<td>Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer</td>
<td>Jhi-Hsiang Lee, Elisa Giovannetti, Jin-Hyeok Hwang, Iacopo Petriti, Quyen Wang, Johannes Voortman, Yonghong Wang, Seth M. Steinberg, Niccola Funel, Paul S. Meltzer, Yisong Wang, and Giuseppe Giaccone</td>
</tr>
<tr>
<td>524</td>
<td>Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas</td>
<td>Harry H. Yoon, Qian Shi, William R. Sukov, Anne E. Wiktor, Malha Khan, Christopher A. Sattler, Axel Grothey, Tsung-Teh Wu, Robert B. Diasio, Robert B. Jenkins, and Frank A. Sinicrope</td>
</tr>
<tr>
<td>555</td>
<td>Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma</td>
<td>John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazzulina, Karin Kemsley, and Reinhard Dummer</td>
</tr>
</tbody>
</table>
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty, Patricia M. LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia S. Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O'Dwyer, and Gary K. Schwartz

A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303

 Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non–Small Cell Lung Cancer Patients
Klaus W. Wagner, Yuanqing Ye, Jie Lin, Ara A. Vaporciyan, Jack A. Roth, and Xifeng Wu

ABOUT THE COVER

Although antiangiogenic therapies are effective and comparatively safe treatments against human cancer, renal toxicity is one of the major concerns. Anti-VEGFR2 immunoliposomes loaded with a chemotherapeutic drug showed marked antitumor activity in various tumor models. Importantly, no long-term renal side effects were evident with this therapy. This image shows a section of mouse kidneys 18 months after repeated injection of anti-VEGFR2 immunoliposomes loaded with doxorubicin. For details, see the article by Wicki and colleagues on page 454 of this issue.